Indications for: LEQEMBI
Alzheimer’s disease in mild cognitive impairment or mild dementia.
Confirm the presence of amyloid beta pathology prior to initiation. Give 10mg/kg by IV infusion over ~1hr, once every 2 weeks. Dosing recommendations for patients with amyloid related imaging abnormalities -edema (ARIA-E) and -hemosiderin deposition (ARIA-H): see full labeling.
Risk of amyloid related imaging abnormalities (ARIA); with edema (ARIA-E) or with hemosiderin deposition (ARIA-H). Obtain a recent MRI (within 1yr) prior to initiation, and prior to 5th, 7th, and 14th infusions. Perform clinical evaluation if ARIA symptoms occur (esp during 1st 14 weeks), including MRI scanning if indicated. Patients with risk factors for intracerebral hemorrhage (eg, prior cerebral hemorrhage >1cm in greatest diameter, >4 microhemorrhages, superficial siderosis, evidence of vasogenic edema, evidence of cerebral contusion, aneurysm, vascular malformation, infective lesions, multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel or white matter disease). Discontinue or reduce infusion rate if an infusion-related reaction occurs. Consider prophylaxis with antihistamines, APAP, NSAIDs, or corticosteroids prior to future infusions. Pregnancy. Nursing mothers.
Amyloid beta-directed antibody.
Caution with concomitant antithrombotics or a thrombolytic agent (eg, tissue plasminogen activator).
Infusion-related reactions, headache, ARIA-E, cough, diarrhea.
The terminal half-life is 5 to 7 days.
Generic Drug Availability:
Single-dose vial (2mL, 5mL)—1